BML-280
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


BML-280
Description:
BML-280 (VU0285655-1) is a potent and selective phospholipase D2 (PLD2) inhibitor. BML-280 has the ability to prevent caspase-3 cleavage and reduction in cell viability induced by high glucose. BML-280 can be used for rheumatoid arthritis research[1][2].Product Name Alternative:
VU0285655-1UNSPSC:
12352005Target:
Interleukin Related; Phospholipase; TNF ReceptorType:
Reference compoundRelated Pathways:
Apoptosis; Immunology/Inflammation; Metabolic Enzyme/ProteaseApplications:
Metabolism-sugar/lipid metabolismField of Research:
Cancer; Metabolic Disease; Inflammation/ImmunologyAssay Protocol:
https://www.medchemexpress.com/bml-280.htmlPurity:
99.64Solubility:
DMSO : 125 mg/mL (ultrasonic)Smiles:
O=C(C1=CC2=CC=CC=C2N=C1)NCCN(CC3)CCC3(N(C4=CC=CC=C4)CN5)C5=OMolecular Formula:
C25H27N5O2Molecular Weight:
429.51References & Citations:
[1]Burkhardt U, et al. Role of phospholipases D1 and 2 in astroglial proliferation: effects of specific inhibitors and genetic deletion. Eur J Pharmacol. 2015 Aug 15;761:398-404. |[2]Tenconi PE, et al. High glucose-induced phospholipase D activity in retinal pigment epithelium cells: New insights into the molecular mechanisms of diabetic retinopathy. Exp Eye Res. 2019 Jul;184:243-257.|[3]Tsai YR, et al. Inhibition of formyl peptide-stimulated phospholipase D activation by Fal-002-2 via blockade of the Arf6, RhoA and protein kinase C signaling pathways in rat neutrophils. Naunyn Schmiedebergs Arch Pharmacol. 2013 Jun;386 (6) :507-19.Shipping Conditions:
Blue IceStorage Conditions:
-20°C, 3 years (Powder)Scientific Category:
Reference compound1Clinical Information:
No Development ReportedIsoform:
IL-1; IL-8; PLD; TNFRSF5/CD40CAS Number:
[1158347-73-9]
